RFG - ETF AI Analysis
Top Page
Invesco S&P Midcap 400 Pure Growth ETF (RFG)
RFG, the Invesco S&P Midcap 400 Pure Growth ETF, earns a solid overall rating thanks to several strong growth-focused holdings like TechnipFMC, Medpace, Valaris, and ATI, which show robust financial performance, positive earnings sentiment, and supportive technical trends. The rating is held back somewhat by weaker names such as Arrowhead Pharmaceuticals and DigitalOcean, where financial challenges, high leverage, and valuation concerns introduce more risk. The main risk factor for the fund is its tilt toward mid-cap growth companies with stretched valuations and some highly leveraged balance sheets, which can increase volatility and downside risk in tougher market conditions.
RFG vs. SPDR S&P 500 ETF (SPY)
- AUM
- 314.89M
- Region
- North America
- Expense Ratio
- 0.35%
- Beta
- 1.04
- Issuer
- Invesco
- Inception Date
- Mar 01, 2006
- Dividend Yield
- 0.12%
- Asset Class
- Equity
- Index Tracked
- S&P Mid Cap 400 Pure Growth
RFG Summary
RFG is the Invesco S&P Midcap 400 Pure Growth ETF, which follows the S&P Mid Cap 400 Pure Growth index. It focuses on medium‑sized U.S. companies with strong growth potential in areas like health care, industrials, and technology. Some of its well‑known holdings include Five Below and DigitalOcean. Investors might consider RFG if they want growth and diversification across many mid‑size companies instead of picking individual stocks. However, because it targets growth stocks, the ETF’s price can move up and down more sharply than the overall market, and returns are not guaranteed.
How much will it cost me?
This ETF has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 you invest. That’s a bit higher than the cheapest index ETFs because it follows a more specialized mid-cap growth strategy rather than a plain-vanilla broad market index.
What would affect this ETF?
RFG could benefit if the U.S. economy continues to grow, supporting mid-sized health care, industrial, and technology companies like Halozyme and Medpace, and if investor appetite for growth stocks remains strong as interest rates stabilize or decline. On the downside, higher interest rates, an economic slowdown, or regulatory pressures on health care and energy could hurt these mid-cap growth names and make this ETF more volatile than broader, more diversified funds.
RFG Top 10 Holdings
RFG is leaning hard into U.S. mid-cap growth, with a clear tilt toward health care and industrial innovators. Halozyme, Medpace, and Exelixis are helping power the fund, riding solid momentum in biotech and clinical research. On the industrial and energy side, Valaris and TechnipFMC have been steadily adding fuel to returns. The main speed bumps come from Arrowhead Pharmaceuticals and DigitalOcean, both lagging lately despite promising long-term stories. Overall, the ETF’s performance is being driven by a concentrated cluster of rising mid-cap health care and energy names.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 HALO | Halozyme | 2.92% | $8.83M | $13.96B | 51.53% | 73Outperform |
 MEDP | Medpace Holdings | 2.27% | $6.86M | $17.76B | 10.29% | 79Outperform |
 FTI | TechnipFMC | 2.16% | $6.51M | $23.95B | 49.88% | 80Outperform |
 FIVE | Five Below | 2.02% | $6.11M | $13.28B | 59.94% | 76Outperform |
 EXEL | Exelixis | 1.98% | $5.97M | $16.77B | 70.51% | 78Outperform |
 ARWR | Arrowhead Pharmaceuticals | 1.93% | $5.82M | $8.12B | 46.87% | 57Neutral |
 VAL | Valaris | 1.91% | $5.76M | $5.37B | 47.50% | 76Outperform |
 IDCC | InterDigital | 1.82% | $5.49M | $7.38B | -25.08% | 76Outperform |
 WWD | Woodward | 1.80% | $5.44M | $18.12B | 20.15% | 79Outperform |
 ATI | ATI | 1.80% | $5.44M | $22.86B | 82.71% | 78Outperform |
RFG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RFG, the sentiment is Negative. The current price of 54.53 is below the 20-day moving average (MA) of 57.50, below the 50-day MA of 58.91, and below the 200-day MA of 59.51, indicating a bearish trend. The MACD of -0.95 indicates Positive momentum. The RSI at 30.73 is Neutral, neither overbought nor oversold. The STOCH value of 32.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RFG.
RFG Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| RFG | $54.53 | $65.00(19.20% Upside) | $314.89M | 0.35% | 73Outperform |
 FNY | $95.55 | $122.25(27.94% Upside) | $557.49M | 0.73% | 67Neutral |
 NUMG | $42.86 | $56.72(32.34% Upside) | $311.48M | 0.31% | 69Neutral |
 GLRY | $36.05 | $46.72(29.61% Upside) | $154.78M | 0.80% | 74Outperform |
 FRTY | $20.18 | $26.98(33.68% Upside) | $136.47M | 0.60% | 61Neutral |
 TMFM | $22.20 | $27.08(21.96% Upside) | $113.36M | 0.85% | 67Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RFG | Invesco S&P Midcap 400 Pure Growth ETF | 54.53 | 2.38 | 4.56% | |
| FNY | First Trust Mid Cap Growth AlphaDEX Fund | 95.55 | 3.65 | 3.97% | |
| NUMG | Nuveen ESG Mid-Cap Growth ETF | 42.86 | -5.06 | -10.55% | |
| GLRY | Inspire Faithward Mid Cap Momentum ESG ETF | 36.05 | -0.61 | -1.67% | |
| FRTY | Alger Mid Cap 40 ETF | 20.18 | -1.83 | -8.31% | |
| TMFM | Motley Fool Mid-Cap Growth ETF | 22.20 | -1.41 | -5.98% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.